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 Patients of African origin who contract HDV less often have
cirrhosis.
 Patients with HDV and detectable viral load have worse
clinical outcomes.
 Patients with HDV genotype 5 less often develop hepatic
decompensation.
 Patients with HDV genotype 5 seem to respond better to
peg-IFN treatment.https://doi.org/10.1016/j.jhep.2019.12.028
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Hepatitis delta is a virus that affects the
liver. The virus is known to have different
subtypes, called genotypes. With this
research we discovered that hepatitis delta
virus genotype 1 behaves differently than
genotype 5 and causes faster development
of liver disease. This is important for edu-
cation of our patients and to determine
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Rotterdam, the NetherlandsBackground & Aims: Coinfection with HDV causes rapid pro- development of liver disease. This is important for education of
gression to liver cirrhosis and hepatic decompensation in pa-
tients with chronic hepatitis B. Factors that are associated with
disease progression are poorly understood. In this study we aim
to identify risk factors associated with disease progression and
better characterise clinical differences and treatment response
between HDV genotype 1 and 5.
Methods: In this retrospective study, all patients under our care
between 2005 and 2016 with HBV/HDV coinfection (HBsAg+,
anti-HDV antibodies positive) were analysed. Patients were
excluded if follow-up was less than 6 months, if they had HCV
and/or HIV coinfection or an acute HDV infection. Demographic
data, stage of liver disease, development of liver complications
and treatment response were recorded.
Results: One-hundred seven patients (mean age 36.0 years, 57%
male) were followed for a median period of 4.4 years (range
0.6–28.1 years); 64% were of African origin and 17% were of
European origin, with 28% of patients being cirrhotic at first visit;
43% patients had actively replicating HDV virus (anti-HDV-IgG+,
anti-HDV-IgM+ or HDV RNA+) and 57% of patients were HDV
exposed (anti-HDV-IgG+, HDV RNA-). Patients with actively
replicating HDV more often developed liver complications than
HDV-exposed patients (p = 0.002), but no differences in baseline
characteristics were observed. Patients with HDV genotype 5 less
often developed cirrhosis or hepatic decompensation compared
to patients with HDV genotype 1. Twenty-four patients were
treated with peg-IFN and post-treatment response was signifi-
cantly better in patients infected with genotype 5 (10% GT1 vs.
64% GT5, p = 0.013).
Conclusion: Patients infected with HDV genotype 5 appear to
have a better prognosis with fewer episodes of hepatic decom-
pensation and better response to peg-IFN treatment than pa-
tients infected with HDV genotype 1.
Lay summary: Hepatitis delta is a virus that affects the liver. The
virus is known to have different subtypes, called genotypes. With
this research we discovered that hepatitis delta virus genotype 1
behaves differently than genotype 5 and causes fasterwords: Hepatitis B virus; HBsAg; Anti-HDV-IgG; HDV RNA; Liver
ompensation.
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Introduction
Hepatitis delta virus (or HDV) is a single stranded RNA virus that
infects around 15–20 million people worldwide.1 It is under-
diagnosed and is the severest form of viral hepatitis with no
effective treatment currently available. The virus is dependent on
HBsAg for packaging and propagation of its virions, although
HDV replication independent of HBV has been shown in liver
transplant patients.2 HDV often leads to the accelerated pro-
gression to advanced hepatic fibrosis, increased risk of hepato-
cellular carcinoma and rapid decompensation.3,4 The prevalence
varies greatly between regions, with rates from 0% to 40% in
HBsAg-positive patients. HDV is known to be endemic in Medi-
terranean countries, the Middle East, parts of Brazil, Mongolia
and central Africa.1,5 Due to the implementation of HBV vacci-
nation programs, the incidence of HDV has significantly
decreased in Europe. However, due to increased migration of
people from highly endemic areas, this decline has recently
reversed.6–8 It is well known that patients with actively repli-
cating delta i.e. those with detectable HDV RNA, have more se-
vere liver disease than those who are anti-HDV-IgG alone. To
diagnose an actively replicating HDV infection in places where
HDV RNA testing is not available, anti-HDV-IgM can be used.9,10
Little is known about the factors influencing spontaneous
clearance of HDV RNA. Besides host factors, virus genotypic
variability might be involved. Eight different genotypes were
identified with 20–40% sequence divergence. Genotype 1 is the
most prevalent and found worldwide. And while genotype 1 is
the most prevalent in Africa, genotypes 5-8 are found exclusively
in African patients and those who migrated to Europe.11–13 A
small number of studies have reported differences in clinical
outcome between hepatitis delta genotypes.14–17 The only
available treatment option for HDV is pegylated interferon-alfa
(peg-IFN), with only 15%–35% of patients achieving a sustained
virologic response (SVR).18–21 Baseline factors that predict clin-
ical outcomes are poorly defined.
In this study we aim to better characterise disease progres-
sion and treatment response in a mixed cohort of patients of
predominantly European and African origin, as well as to identify
















• FU <6 months or <3 visits
• HIV and/or
• HCV coinfection
• Acute HBV/HDV infection
Fig. 1. Demographic characteristics and exclusion criteria of the patients at
entry and development of liver-related endpoints along follow-up.
Research Article Viral HepatitisPatients and methods
Patient population
Between January 2005 and December 2016, all 4,977 HBsAg-
positive patients attending the outpatient clinic in King's College
Hospital, London were routinely screened for anti-HDV-IgG. Two-
hundred and one patients (4.6%) were found to be positive and
were further analysed for our study (Fig. 1). The following groups
were excluded: 14 HIV coinfected patients, 4 patients with HCV
coinfection (HCV RNA+) and 76 patients with follow-up for less
than 6 months or less than 3 consecutive visits. In addition, 4 pa-
tients with HDV superinfection at diagnosis were excluded from
the study. From 107 patients, clinical characteristics and liver-
related endpoints were recorded. Cirrhosis was defined by liver
biopsy (ISHAK score >−F5), transient elastography (>12.5kPa on
Fibroscan) or if patients had signs of cirrhosis via radiological
criteria. This observational single centre study was conducted
following the ethical principles of the Declaration of Helsinki and
had ethical approval.
Virological testing
Serological markers of HBV, HCV and HIV were tested by com-
mercial Chemiluminescent microparticle immunoassays (CMIAs)
on Abbott ARCHITECT i2000 SR (Abbott Laboratories, North
Chicago, IL). Anti-HDV-IgG, anti-HDV-IgM were tested using ETI-
DELTA-IGMK-2 and ETI-AB-DELTAK-2 (Diasorin S.p.A 13040 Sal-
uggia (vc), Italy). HDV RNA and HDV genotype were tested using
an in-house quantitative HDV RNA assay with a lower limit of
quantification of 640 IU/ml,22 direct sequencing using ABI 3130×l
genetic analyser (Life Technologies, Carslbad, CA) and phyloge-
netic tree analysis using neighbour-joining (NJ) distance analyses
software (njplot, v 2.0). HBV DNA was tested using the Roche
Cobas AmpliPrep/Cobas TaqMan assay with a lower limit of
quantification of 20 IU/ml. HBV genotypes were determined by
in-house nucleic acid amplification and direct sequencing using
an ABI 3130×l genetic analyser (Life Technologies, Carslbad, CA).
Since HDV RNA levels are known to fluctuate over time, patients
were classified as having actively replicating HDV infection if
HDV RNA was detected once during follow-up and/or anti-HDV-
IgM was positive. For missing data, stored samples were retested
using the assays above. Patients were classified as HDV exposed
if HDV RNA was undetectable during follow-up for at least 3
repeated measured and anti-HDV-IgM was negative.
Statistical analyses
For normally distributed variables, unpaired t test was used for
unpaired data. Paired continuous variables that were not nor-
mally distributed were assessed byWilcoxon's rank-sum test and
unpaired variables by the Mann-Whitney U test. Categorical data
were compared using Fisher's exact test. Survival was calculated
using Kaplan-Meier's method and compared using log-rank test.
Spearman rank correlation test was used to calculate a correla-
tion between 2 non-parametric values. Hazard ratios (HRs) were
calculated using Cox proportional Hazard model. Statistical sig-
nificance was considered at a p <0.05 level. All analyses were
performed using SAS software (v9.4; SAS institute, Inc., Cary, NC.)
Results
Baseline demographics
A total of 107 patients were included in our study (mean age 36.0
years [range 16.5–61.7 years]). Patients' clinical and demographic2 Journal of Hepatologcharacteristics are shown in Table 1. Interestingly, in contrast to
other studies from Europe,23–25 that mainly reported on patients
born in Eastern Europe and Central Asia, our cohort consists of a
large population born in (West or sub-Saharan) Africa (64.5%).
There were 2 different patterns of HBV and HDV genotype dis-
tribution in our cohort. There was a strong correlation between
HDV and HBV genotype (p <0.001) and origin (p <0.001); patients
with HBV genotype D were mostly infected with HDV genotype 1
(10/10, 100%) in contrast to patients with HBV genotype E who
were all infected with HDV genotype 5 (13/13, 100%). Forty-three
(40.4%) patients had detectable HDV RNA levels during their
follow-up and 33 (30.6%) patients had positive anti-HDV-IgM. All
patients with detectable HDV RNA and/or anti-HDV-IgM were
classified as having actively replicating HDV infection. As ex-
pected, patients who were only HDV exposed (undetectable HDV
RNA and negative anti-HDV-IgM) had significantly less cirrhosis
(p <0.001), and appeared to have less advanced liver disease with
lower aspartate aminotransferase (p <0.001), alanine amino-
transferase (ALT; p <0.001), bilirubin (p = 0.037), international
normalized ratio (p = 0.008) and higher albumin (p = 0.042)
compared to patients with actively replicating HDV (Table 1). In
addition, 78% of HDV-exposed patients had normal ALT (<45 IU/
ml) upon presentation. The baseline event-anticipation (BEA)
score, designed to calculate the risk of developing a liver-related
complication in 5 years, was calculated for all groups (Table 1).
The presence of cirrhosis at first visit was significantly different
between patients of African (n = 12, 17.4%), Asian (n = 5, 38.5%)
and European origin (n = 9, 50%, p = 0.023). However, no dif-
ferences were observed for age, time of follow-up, gender or HBV
genotype between HDV-exposed patients and patients who had
actively replicating HDV (Table 1). On the first visit, 11 patients
(10%) were on nucleos(t)ide analog (NUC) treatment: 3 patients
on tenofovir, 5 on entecavir, 1 on a combination of lamivudine
and adefovir and 2 on peg-IFN/tenofovir. On the last visit 42
patients (39%) were on NUC treatment.Disease progression
All patients with anti-HDV-IgG were followed for a median
period of 4.4 years (range 0.6–28.1 years). Among the 77 patients
that did not have cirrhosis at baseline, 2 patients progressed to
cirrhosis. At baseline, 2 patients were already decompensated
and 8 patients experienced at least 1 episode of liver decom-
pensation during follow-up (Table S1). Liver decompensation
throughout this study is defined as Child-Pugh >B7 or they 2020 vol. - j 1–8
Table 1. Baseline characteristics between HDV-exposed patients and those with actively replicating HDV.
All patients Exposed HDV
undetectable HDV RNA
Actively replicating HDV
detectable HDV RNA and/or anti-HDV-IgM
p value*
Number 107 61 46
Age years, mean ± SD (range) 36.0 ± 10.4 (16.5–61.7) 36.6 ± 4.7 (17.3–61.7) 35.1 ± 10.4 (16.5–59.8) 0.493
Gender, male 57 (53.3) 30 (49.2) 27 (58.7) 0.218














HBV genotype 7 A 2 C
22 D 53 E
4 A 1 C
12 D 36 E
3 A 1 C
10 D 17 E
0.688
HBeAg positive 10 (9.4) 6 (9.8) 4 (8.9) 0.573
HBsAg level IU/ml 6.4×103 (0.03–1.1×105) 6.8×103 (0.03–2.7×104) 6.4×103 (544–1.1×105) 0.695
HBV DNA IU/ml 50.1 (0–1.8×108) 91.1 (0–1.7×108) 32 (0–1.8×108) 0.138
HDV genotype 18 GT1
21 GT5
61 unknown 18 GT1
21 GT5
HDV RNA IU/ml 0 (0–8.7×108) 0 (0–0) 4.2E4 (0–8.7×106) <0.001
Detectable HDV RNA 43 (40.2) 0 43 (93.4) <0.001
Detectable anti-HDV-IgM 33 (31.4) 0 33 (73.3) <0.001
Cirrhosis 30 (28) 7 (11.5) 23 (50) <0.001
ALT IU/L 40.0 (2–573) 25.0 (2–185) 66.0 (14–573) <0.001
AST IU/L 36.0 (13–372) 29.0 (13–342) 58.0 (24–372) <0.001
Platelets × 10
ˇ
9/L 192.0 (28–372) 197.0 (95–372) 171.5 (28–332) 0.045
Bilirubin lmol/L 10.0 (3–257) 9.0 (3–24) 11.0 (3–257) 0.037
Albumin mmol/L 44.0 (21–83) 44.0 (27–49) 43.0 (21–83) 0.042
INR 1.1 (0.9–2.7) 1.0 (0.9–1.4) 1.1 (0.9–2.7) 0.008










Data presented as median (range), or n (%) unless stated otherwise.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BEA, baseline event-anticipation; GT, genotype; INR, international normalised ratio.
*Comparison made between patient groups with exposed and actively replicating HDV infection. For normally distributed variables (age), unpaired t test was used. For data
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Fig. 2. Cumulative event-free survival in patients who are HDV exposed or
have actively replicating HDV. Survival was calculated using Kaplan-Meier's
method and compared using log-rank test. HCC, hepatocellular carcinoma.
Journal of Hepatologpresence of ascites or a variceal bleed. Nine patients developed
ascites and 4 patients had a variceal bleed. Six patients devel-
oped hepatocellular carcinoma (HCC), all diagnosed within 3
months of the first visit. Seven patients required a liver trans-
plant and 2 patients died of a liver-related event (Fig. 1, Table S1).
Time to development of a liver-related event was strongly
associated with the presence of cirrhosis (p <0.001), but not with
HBeAg status (p = 0.443), HBV genotype (p = 0.157), having
detectable HBV DNA (p = 0.459, all Kaplan Meier survival anal-
ysis) or age (r = −0.17; p = 0.079, Spearman correlation test).Comparison between patients with actively replicating HDV or
exposure to HDV
Patients with actively replicating HDV developed significantly
more episodes of decompensation (p = 0.002), ascites (p = 0.005)
variceal bleeding (p = 0.032) and more often received a liver
transplant (p = 0.043) compared to HDV-exposed patients during
follow-up (Table S1). Survival analysis showed that HDV-exposed
patients had better liver event-free survival compared to patients
with actively replicating HDV (Fig. 2). Because of the low event
score, HRs were only calculated for composite clinical events
(decompensation, HCC, liver transplantation and mortality). The
HR for exposed vs. active HDV was 7.29 (95% CI 2.43–21.87; p =
0.0024). In line with the lower presence of cirrhosis, patients of
African origin less frequently developed decompensation
compared to patients of European or Asian origin in survival ana-
lyses (Fig. S1). No differences in baseline factors such as platelet
count, alkaline phosphatase levels, fibroscan results, fibrosis-4
(FIB-4) or albumin-bilirubin (ALBI) scores were observed be-
tween African vs. non-African patients (results not shown).y 2020 vol. - j 1–8 3
Table 2. Patient characteristics of patients with HDV genotype 1 and 5.
HDV genotype 1 HDV genotype 5 p value
Number 18 21
Age, years 36.9 (16.5–59.8) 33.3 (17.4–43.6) 0.215
Gender, male 11 (61.1) 13 (61.9) 1.000
Follow-up, years 4.7 (1.2–14.1) 4.7 (0.6–11.7) 0.955
Origin 9 Europe 5 Asia
2 Africa 2 unknown
0 Europe 0 Asia
21 Africa
<0.001
HBV genotype 1 A 10 D
0 E 7 unknown
1 A 0 D
13 E 7 unknown
<0.001
HBeAg positive 1 (5.6) 3 (14.3) 0.609
HBsAg level IU/ml 3.9×103 (544–2.9×104) 7.0×103 (1.1×103–1.1×105) 0.432
HBV DNA IU/ml 10.25 (0–4.4×106) 36.5 (0–1.8×108) 0.184
HDV RNA IU/ml 6.9×104 (0–8.3×105) 2.7×105 (944–8.7×106) 0.477
Detectable HDV RNA, % 100 100 1.000
Detectable anti-HDV-IgM 17 (94.4) 13 (61.9) 0.023
Cirrhosis 12 (66.7) 6 (28.6) 0.026
ALT IU/L 66.0 (39–126) 90.5 (32–573) 0.338
AST IU/L 61.0 (34–175) 55 (28–513) 0.693
Platelets *10
ˇ
9/L 163.0 (48–332) 201.0 (28–321) 0.115
Bilirubin lmol/L 12.0 (5–63) 11.0 (3–33) 0.224
Albumin mmol/L 42.5 (21–50) 43.0 (25–83) 0.524
INR 1.1 (0.9–1.6) 1.1 (0.9–1.4) 0.489
FIB-4 scores 1.11 (0.3–7.4) 1.29 (0.4–6.8) 0.942
ALBI score –2.97 (–3.3–0.6) –2.97 (–6.4–1.8) 0.464







Data presented as median (range), or n (%) unless stated otherwise.
ALBI, albumin-bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BEA, baseline event-anticipation; FIB-4, fibrosis-4; INR, international normalised
ratio.
*For normally distributed variables (age), unpaired T test was used. For data that were not normally distributed, Mann-Whitney U test was used. Categorical data were
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Fig. 3. Cumulative event free survival in patients who have HDV genotype 1
or HDV genotype 5. Survival was calculated using Kaplan-Meier's method and
Research Article Viral HepatitisHDV genotype 5 is associated with favourable disease progression
compared to HDV genotype 1
Of 43 patients with actively replicating HDV, 39 patients had
samples available for genotyping; 21 patients were found to have
genotype 1 and 18 patients were infected with genotype 5
(Table 2). As expected, most patients with genotype 5 were of
African origin (100%) and had HBV genotype E (93%) whereas
patients with genotype 1 were predominantly of European origin
(56%) and were infected with HBV genotype D (91%). Age, gender
and median follow-up time were similar for both groups. Levels
of HBV DNA were low and comparable in both groups and no
differences were observed in levels of HDV RNA and HBsAg. The
ALBI and the FIB-4 score were calculated and showed no differ-
ences. Interestingly, although patients of both genotypes had
comparable liver function tests, the presence of liver cirrhosis at
the time of diagnosis was more prevalent in patients with ge-
notype 1 infection (p = 0.026, Table 2). At first visit, patients with
HDV genotype 1 tended to have higher BEA-scores, but this did
not reach statistical significance. During follow-up, patients with
HDV genotype 1 were more likely to develop an episode of he-
patic decompensation (p = 0.001), and to receive a liver trans-
plant (p = 0.025, Fig. 3, Table S2). HR was calculated for
composite clinical events (decompensation, HCC, liver trans-
plantation and mortality). HR for genotype 5 vs. genotype 1 was
5.40 (95% CI 1.65–17.70) with a p value of 0.015. Focussing only
on patients with cirrhosis, none of the 6 patients with genotype
5 developed hepatic decompensation during follow-up, while 7
out of 12 (58%) patients with genotype 1 developed liver
decompensation (p = 0.038).compared using log-rank test.
4 Journal of Hepatology 2020 vol. - j 1–8
Table 3. Patients characteristics of patients that underwent peg-interferon treatment.
All patients Non-response Response p value*
Number 25 14 11 0.695
Age years 33.9 (17.8-52.3) 30.0 (17.8-50.1) 34.5 (22.1-52.3) 0.200
Gender, male 12 (48) 6 (43) 6 (55) 0.695
Cirrhosis 12 (48) 8 (57) 4 (36) 0.428
HBV genotype 2 A 5 D
11 E
0 A 5 D
4 E
2 A 0 D
7 E
0.032















IFN-treatment weeks 48.0 (9-80) 48.0 (18-80) 48.0 (9-53) 0.267
Follow-up after treatment months 51.2 (6.4-116.5) 49.8 (25.8-116.5) 51.3 (6.4-112.4) 0.936
HDV RNA IU/ml 3.5×105 (0-1.1×108) 5.9×105 (2.9×104-1.1×108) 1.8×104 (0-2.1×106) 0.002
HBV DNA level IU/ml 41.8 (0-1.9×106) 53.8 (0-1.8×105) 0 (0-1.9×106) 0.893
HBsAg level IU/ml 8.3×103 (1.6×103-4.6×104) 8.7×103 (2.6×103-4.6×104) 6.8×103 (1.6×103-2.0×104) 0.422
Detectable anti-HDV-IgM 16 (64) 10 (71) 6 (54.5) 0.673
Data presented as median (range), or n (%) unless stated otherwise.
GT, genotype; peg-IFN, pegylated interferon.
*Comparison made between patient groups with response and non-response to Peg-IFN therapy. For normally distributed variables (age), unpaired t test was used. For data








• No baseline data
• FU <6 months post treatment
• HCV co-infection
• Responder-relapser 5 (36%)
• Viral breakthrough 2 (14%)
• Non-responder 7 (50%)
Fig. 4. Demographic characteristics and exclusion criteria of the patients
who were treated with peg-IFN and their response to treatment. peg-IFN,
pegylated interferon.
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Fig. 5. Cumulative event free survival of any episode of liver decompen-
sation in patients with or without a response to peg-IFN treatment.
Survival was calculated using Kaplan-Meier's method and compared using
log-rank test. peg-IFN, pegylated interferon.Antiviral therapy
From our cohort of 201 patients with positive anti-HDV-IgG, 42
patients were treated with peg-IFN. Patients were excluded for
this analysis if baseline data were not available (n = 15), if follow-
up was less than 6 months post treatment (n = 1) or if patients
were coinfected with HCV (n = 1). Twenty-five patients were
included with a median age of 33.9 years (range 17.8–52.3 years).
Patient characteristics at the start of antiviral therapy are shown
in Table 3. None of the patients received peg-IFN therapy in the
past. Median HDV RNA at the start of therapy was 105, compa-
rable to levels at first visit. There was 1 patient with an excep-
tionally high HDV RNA level of 108 who eventually had a non-
response. Ten (40%) patients were infected with HDV genotype
1 vs. 14 (56%) with genotype 5. We were not able to determine
genotype in 1 patient. From 25 treated patients, 16 patients were
HDV RNA negative at the end of therapy: 11 patients maintained
HDV RNA status more than 6 months after completing therapy
but 14 patients had a non-response; 5 patients relapsed – 4
within 6 months after stopping therapy and 1 patient relapsed
after 22 months; 2 had a viral breakthrough on therapy and 7
patients were total non-responders (Fig. 4). HBsAg levels
decreased during peg-IFN treatment but this was not statistically
significant (Table 3) and no seroconversions were observed.
Baseline characteristics of both responders and non-
responders did not differ by age, gender or presence ofJournal of Hepatologcirrhosis. Differences were found for HBV genotype (p = 0.032)
and baseline HDV RNA level (p = 0.002, Table 3). Patients from
Africa tended to respond better to peg-IFN, but this did not reach
statistical significance (p = 0.078). Duration of peg-IFN treatment
was significantly shorter in patients with genotype 5 compared
to genotype 1 (median duration was 48 weeks for both geno-
types, but mean duration was 38 weeks vs. 54 weeks, p = 0.007).
Treatment was discontinued for various reasons including
pregnancy, poor adherence and side-effects. Strikingly, although
treatment durationwas shorter in patients with HDV genotype 5,
6-month response rates after stopping therapy were higher in
comparison to patients with genotype 1 infection (64% genotype
5 vs. 10% genotype 1, p = 0.013, Table 3). Survival analysis showed
that treatment response was associated with improved clinical
outcome at follow-up (p = 0.043, Fig. 5).Discussion
This study evaluated the clinical outcomes of a diverse patient
population with positive anti-HDV-IgG antibodies in the United
Kingdom. The proportion of HBsAg-positive patients with posi-
tive anti-HDV total antibodies was 4.3%. Surprisingly, only 43% ofy 2020 vol. - j 1–8 5
Research Article Viral Hepatitisanti-HDV total positive patients had detectable HDV RNA. The
presence of HDV RNA in serum is required to diagnose actively
replicating HDV infection and is an important factor determining
rapid development of cirrhosis and poor clinical outcome.16,24
One explanation might be a relatively low sensitivity of the
assay used and the possibility that low levels of HDV RNA were
not detected. However, all patients with undetectable HDV RNA
were tested on several occasions repeatedly and were also anti-
HDV IgM negative. Patients in our cohort with undetectable HDV
RNA and anti-HDV-IgM had stable disease and normal or mildly
elevated liver enzymes, indicating they do not have actively
replicating delta infection. Interestingly, none of the patients
with undetectable HDV RNA had received peg-IFN previously
and it is therefore likely that these patients spontaneously
cleared their HDV virus after acute coinfection or superinfection.
The proportion of patients with spontaneous HDV clearance may
even be underestimated since patients who may have cleared
HBsAg are not included in this cohort. To get more insight into
mechanisms involved in clearance of HDV, we compared base-
line characteristics of patients with actively replicating and
exposed HDV, but no differences were observed. It is suspected
that other factors might contribute to spontaneous viral clear-
ance, namely mode of transmission, age at time of contraction
and mode of infection (super vs. coinfection) and it would be of
interest to focus future studies on these aspects. One explanation
for the low proportion of patients with HDV RNA viremia is the
relative high number of patients of African origin. Epidemio-
logical studies from Africa have demonstrated that 35–62% of
patients have detectable HDV RNA in serum,5,26–28 which ap-
pears lower than studies from Europe and Asia that have shown
that 70–93% of patients with anti-HDV-IgG have detectable HDV
RNA levels.16,25,29,30
The ability to clear hepatitis delta is likely to be influenced by
host and viral factors. A small number of studies have reported
differences in clinical outcome between hepatitis delta geno-
types. Independent of HBV genotype, infection with genotype 1
delta seems to be more damaging than genotype 2.15,16 Genotype
3 has been associated with acute liver damage in an area of the
Amazon14 and genotype 4 seems to behave differently in various
regions.15,17 To our knowledge, this is the first study to fully
characterise patients infected with HDV genotype 5 and compare
its disease progression with patients infected with genotype 1. In
this study we provide evidence that African patients have a
milder course of disease compared to non-African HDV patients
on 3 levels. i) African patients less often present with cirrhosis at
first visit compared to non-African patients; ii) African patients
less often developed the clinical hard endpoints such as
decompensation compared to non-African patients and iii)
Resolved HDV occurred more frequently in African patients.
One of the mechanisms that could clarify different outcomes
between patients and HDV genotypes is variability in viral
replication and virion assembly efficacy leading to a lower rate of
HDV virion secretion and therefore slower infection of hepato-
cytes.16,31,32 Host factors like race and single-nucleotide poly-
morphisms causing differences in entry receptors might also
play a role.
Our cross-sectional, single-centre study has limitations as it
focuses only on a small number of patients and is retrospective.
However, this is a hepatitis virus that is poorly understood with
little data on genotypic heterogeneity. It appears that patients of
African origin are more likely to be exposed to HDV than have6 Journal of Hepatologactively replicating HDV. To better understand whether this
difference is due to the variation in HDV genotype, interactions
between specific HBV and HDV genotypes or to the absence of
HDV RNA in circulation in the exposed patients, more prospec-
tive, multicentre studies are needed. In addition, we were not
able to separate the effect of HBV-related damage from HDV as
high concordance between HDV and HBV genotypes was
demonstrated.
In our patients with actively replicating HDV infection, 23
patients (50%) were cirrhotic at first presentation to our centre.
Of the cirrhotic patients, 9 patients (39%) decompensated during
a mean follow-up of 4.8 years, with an incidence rate of 8.0 per
100 person-years. The overall incidence rate of decompensation
episodes was lower than in other studies.24,25,29 Between these
studies, patient characteristics varied greatly but it is possible
that the low incidence of decompensation in our cohort reflects
the high number of patients with genotype 5 who had a lower
rate of decompensation than patients with HDV genotype 1.
Peg-IFN treatment has poor tolerability and factors predicting
the outcome of peg-IFN are not well understood. Some studies
have shown that neither cirrhosis nor liver biochemical tests at
baseline affect the response to treatment,18,33,34 while others
appear to suggest that patients with cirrhosis or advanced dis-
ease respond less well.21,35 Several studies have reported that
after 6 months of therapy, a negative HDV-RNA was predictive of
sustained response.18,36 However, late-relapse often occurs and
negative HDV-RNA 6 months post-treatment does not seem to
predict response or prevent relapse.34 In our cohort, 25 patients
were treated with peg-IFN therapy for a median period of 48
weeks. Eleven patients (44%) had a treatment response, which is
similar to the result of a recent large European trial.20 Treatment
response has been defined as undetectable HDV RNA at least 6
months post-treatment; however this does not seem to be a
reliable end-point and late relapse occurs frequently;34 only loss
of HBsAg could be classed as sustained virological response in
delta patients. Indeed, although most patients relapsed within 6
months post-treatment, 1 patient had a relapse 22 months post-
treatment. Treatment responses are likely to be accurate in our
cohort as there is long-term follow up. Of note, the patient with a
relapse 22 months post-treatment had positive anti-HDV-IgM
during and after treatment, which might suggest an ongoing
antibody response to small amounts of virus that are still present
in concentrations below the detection limit of our HDV RNA
quantitative assay. In future studies anti-HDV-IgM might help to
define treatment response, although in a previous study, anti-
HDV IgM did not show a correlation with level of HDV replica-
tion but did show a correlation with disease activity.10 We show
that treatment response to peg-IFN is associated with lower
disease progression, which is in line with results from Wranke
et al.30 Importantly, patients with genotype 5 appeared to
respond better to peg-IFN treatment than patients with HDV
genotype 1, while treatment duration was slightly shorter. This
was not statistically shown in patients of African origin, most
likely due to the presence of both genotype 1 and 5 in this pa-
tient population. Because of small numbers and retrospective
design, prospective randomized clinical trials including patients
with HDV genotype 5 are required to confirm this clinical
observation.
In summary, this study demonstrates that disease progression
and clinical outcomes are associated with HDV genotypic het-
erogeneity. We demonstrate that patients with HDV genotype 5,y 2020 vol. - j 1–8
predominantly of African origin, have a favourable disease
outcome compared to patients with genotype 1 and appear to
have a better treatment response to peg-IFN. Identifying the risk
factors for decompensation is important for patient education,
clinical management and to delineate patients who need
meticulous follow-up.
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